CClinicalTrials.gg
Not yet recruitingNCT05914051PRELOAD-TAVIUpdated Jun 22, 2023

PRELOAD-TAVI Trial

An interventional study of Colloid preload in TAVI, sponsored by Fundación de investigación HM. Not yet recruiting. Open to participants aged 18 Years to 110 Years. Per ClinicalTrials.gov, last updated 2023-06-22.

Sponsored by Fundación de investigación HM · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Apr 2024, 2 years 6 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 110 Years
Sex
All
01

Study summary

The aim is to assess the response of cardiac output and stroke volume to volume preload optimization in patients with severe aortic stenosis treated with aortic prosthesis implantation.

Read the detailed description

Patients with severe aortic stenosis present a maintained overload pressure of the left ventricle that can lead to a progressive hypertrophy. This results in elevated left-sided filling pressures and impaired diastolic function.In this context, paradoxical changes in left ventricular function after aortic valve replacement have been described, with acute decrease of the afterload condition that can result in the development of a dynamic intraventricular gradient, especially in the presence of small ventricles with severe hypertrophy, resulting in hemodynamic collapse.

In this setting, it is particularly important to ensure accurate left ventricular preload to optimize myocardial contractility and guarantee an adequate hemodynamic response to valve implantation.

Patients with severe aortic stenosis submitted for transfemoral TAVI on spontaneous breathing will be randomly assigned 1:1 to standard care vs volume preload optimization. Non-invasive continuous monitoring (Clear Sight System, Edwards Lifesciences) will be used to evaluate the cardiac output and the stroke volume in both groups, comparing the hemodynamics before and after valve implant.

02

Conditions studied

  • TAVI
03

In context

Lead sponsor

Fundación de investigación HM is the lead sponsor of 22 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 110 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Aortic valve stenosis with echocardiographic derived criteria: mean gradient >40 mmHg or jet velocity greater than 4.0 m/s or an initial aortic valve area of \< 0.8 cm2

Exclusion criteria

Exclusion Criteria:

  • Cardiogenic shock.
  • Life expectancy \< 1 year.
  • Need of mechanic ventilation.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Volume preload optimization.

    Volume overload with 250 cc saline solution will be performed in the intervention arm, verifying the response of the cardiac output and stroke volume with non invasive continue monitoring.

    Other: Colloid preload

  • No intervention
    Control group

    Standard care without volume preload.

Interventions

  • OtherColloid preload

    250 cc of colloid preload solution will be infused in the intervention group

06

What researchers measure

Primary outcomes

  1. Cardiac output after valve implant

    Cardiac output (l/min) after TAVI

    Time frame: "1 year"

Secondary outcomes

  1. Stroke volume after valve implant

    SV (ml) after TAVI

    Time frame: "1 year"

Other outcomes

  1. Need of inotropes

    Yes/no

    Time frame: "1 year"

  2. HR after TAVI

    rpm

    Time frame: "1 year"

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Csr

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05914051
Lead sponsor
Fundación de investigación HM
Responsible party
Leire Unzue Vallejo (PRELOAD-TAVI Trial, Fundación de investigación HM) — Principal investigator
First posted
Jun 22, 2023
Start date
Oct 1, 2023 (estimated)
Primary completion
Apr 1, 2024 (estimated)
Completion
Jul 1, 2024 (estimated)
Last update
Jun 22, 2023

Study contacts

Leire Unzue, PhD
Contact
leireunzue@yahoo.es
0034917089900
Miguel Rodríguez del Río, MD
Contact
mrrio1980@gmail.com
0034917089900

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion